

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/046278-2025>

Planning

NP49425 Generic and Biosimilar Transition Medicines

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

F01: Prior information notice

Prior information only

Notice identifier: 2025/S 000-046278

Procurement identifier (OCID): ocds-h6vhtk-0581ea

Published 5 August 2025, 4:26pm

Section I: Contracting authority

I.1) Name and addresses

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

1 South Gyle Crescent

Edinburgh

EH12 9EB

Contact

Cameron Wright

Email

cameron.wright@nhs.scot

Telephone

+44 1312756000

Country

United Kingdom

NUTS code

UKM - Scotland

Internet address(es)

Main address

<http://www.nss.nhs.scot/browse/procurement-and-logistics>

Buyer's address

https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

Additional information can be obtained from the above-mentioned address

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NP49425 Generic and Biosimilar Transition Medicines

II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

II.1.3) Type of contract

Supplies

II.1.4) Short description

The Authority seeks to establish a Framework Agreement covering medicines that are imminently approaching or have already reached Loss of Exclusivity (LoE).

The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape):

- Apremilast 30mg tablets
- Axitinib 1mg tablets
- Axitinib 3mg tablets
- Axitinib 5mg tablets
- Axitinib 7mg tablets
- Betaine oral powder
- Denosumab 120mg/1.7ml solution for injection vials
- Denosumab 120mg/1ml solution for injection pre-filled syringes
- Denosumab 60mg/1ml solution for injection pre-filled syringes
- Eltrombopag 25mg oral powder sachets sugar free

- Eltrombopag 25mg tablets
- Eltrombopag 50mg tablets
- Eltrombopag 75mg tablets
- Ferric carboxymaltose 100mg/2ml dispersion for injection vials
- Ferric carboxymaltose 1g/20ml dispersion for injection vials
- Ferric carboxymaltose 500mg/10ml dispersion for injection vials
- Fluticasone furoate 27.5micrograms/dose nasal spray
- Fluticasone propionate 50micrograms/dose / Azelastine 137micrograms/dose nasal spray
- Generic Otezla tablets treatment initiation pack
- Generic Sustanon 250mg/1ml solution for injection ampoules
- Golimumab 100mg/1ml solution for injection pre-filled disposable devices
- Golimumab 50mg/0.5ml solution for injection pre-filled disposable devices
- Golimumab 50mg/0.5ml solution for injection pre-filled syringes
- Lanreotide 120mg/0.5ml solution for injection pre-filled syringes
- Lanreotide 90mg/0.5ml solution for injection pre-filled syringes
- Lanreotide 60mg/0.5ml solution for injection pre-filled syringes
- Mesalazine 1.5g gastro-resistant modified-release granules sachets sugar free
- Mesalazine 1.6g gastro-resistant tablets
- Mesalazine 1g gastro-resistant modified-release granules sachets sugar free
- Mesalazine 1g modified-release granules sachets sugar free
- Mesalazine 1g modified-release tablets
- Mesalazine 1g suppositories

- Mesalazine 1g/100ml enema
- Mesalazine 1g/application foam enema
- Mesalazine 250mg gastro-resistant tablets
- Mesalazine 2g modified-release granules sachets sugar free
- Mesalazine 2g/59ml enema
- Mesalazine 400mg gastro-resistant tablets
- Mesalazine 4g modified-release granules sachets sugar free
- Mesalazine 500mg gastro-resistant modified-release granules sachets sugar free
- Mesalazine 500mg gastro-resistant tablets
- Mesalazine 500mg suppositories
- Mesalazine 800mg gastro-resistant tablets
- Nilotinib 150mg capsules
- Nilotinib 200mg capsules
- Nilotinib 50mg capsules
- Nintedanib 100mg capsules
- Nintedanib 150mg capsules
- Omalizumab 150mg/1ml solution for injection pre-filled syringes
- Omalizumab 75mg/0.5ml solution for injection pre-filled syringes
- Omalizumab 300mg/2ml solution for injection pre-filled disposable devices
- Omalizumab 300mg/2ml solution for injection pre-filled syringes
- Pazopanib 200mg tablets
- Pazopanib 400mg tablets

- Perampanel 10mg tablets
- Perampanel 12mg tablets
- Perampanel 2mg tablets
- Perampanel 4mg tablets
- Perampanel 500micrograms/ml oral suspension sugar free
- Perampanel 6mg tablets
- Perampanel 8mg tablets
- Pertuzumab 420mg/14ml solution for infusion vials 1 vial
- Testosterone undecanoate 1g/4ml solution for injection ampoules
- Testosterone undecanoate 1g/4ml solution for injection vials
- Ticagrelor 60mg tablets
- Ticagrelor 90mg orodispersible tablets sugar free
- Ticagrelor 90mg tablets
- Tocilizumab 162mg/0.9ml solution for injection pre-filled disposable devices
- Tocilizumab 162mg/0.9ml solution for injection pre-filled syringes
- Tocilizumab 200mg/10ml solution for infusion vials
- Tocilizumab 400mg/20ml solution for infusion vials
- Tocilizumab 80mg/4ml solution for infusion vials
- Trabectedin 1mg powder for solution for infusion vials
- Trabectedin 250microgram powder for solution for infusion vials

II.1.5) Estimated total value

Value excluding VAT: £131,244,104

II.1.6) Information about lots

This contract is divided into lots: Yes

II.2) Description

II.2.1) Title

Cancer Medicines (Group 2)

Lot No

8

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of cancer medicines (Group 2) to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.2) Description

II.2.1) Title

Cytokine Modulators

Lot No

1

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of cytokine modulators to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.2) Description

II.2.1) Title

Gastrointestinal, Endocrine, Nutrition, Blood, and Multiple Sclerosis Medicines

Lot No

2

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of gastrointestinal, endocrine, nutrition, blood, and multiple sclerosis medicines NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.2) Description

II.2.1) Title

Denosumab (osteoporosis)

Lot No

3

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of denosumab (osteoporosis) to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.2) Description

II.2.1) Title

Apremilast

Lot No

4

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of apremilast to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.2) Description

II.2.1) Title

Cardiovascular and Respiratory Medicines

Lot No

5

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and

any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of cardiovascular and respiratory medicines to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.2) Description

II.2.1) Title

Nintedanib

Lot No

6

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of nintedanib to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.2) Description

II.2.1) Title

Cancer Medicines (Group 1)

Lot No

7

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of cancer medicines (Group 1) to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.2) Description

II.2.1) Title

Neurology Medicines

Lot No

9

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of neurology medicines to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.3) Estimated date of publication of contract notice

15 August 2025

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section VI. Complementary information

VI.3) Additional information

The estimated values referred to in Section II.1.5 cover maximum forty-eight (48) month duration of the Framework Agreement (comprised of the initial duration and any extension duration(s) combined).

NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at

https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=801883.

(SC Ref:801883)